ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "inflammatory arthritis and interleukins (IL)"

  • Abstract Number: 946 • 2013 ACR/ARHP Annual Meeting

    Interleukin-34 Regulates Angiogenesis and Cell Proliferation In Inflammatory Arthritis, This Effect Is Potentiated By Hypoxia

    Emese Balogh1, Mary Connolly1, Monika Biniecka1, Jennifer McCormick2, Douglas J. Veale3 and Ursula Fearon2, 1Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland

    Background/Purpose: Interleukin-34 (IL-34) is a cytokine implicated in macrophage differentiation, angiogenesis and osteoclastogenesis in inflammatory arthritis (IA). IA is characterized by synovial hypoxia, increased oxidative…
  • Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT

    T. Bardin1, A. So2, R. Alten3, M. Bloch4, M. R. John5, G. Krammer5, J. M. Nebesky5, A. Tao6 and N. Schlesinger7, 1Service de Rhumatologie, Hôpital Lariboisière, Paris, France, 2Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, 3Charité Univ Medicine, Berlin, Germany, 4Holdsworth House Medical Practice, Sydney, Australia, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…
  • Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting

    Long-Term Safety of Canakinumab in Patients with Gouty Arthritis

    Alexander So1, Reike Alten2, H. Ralph Schumacher3, Mark Bloch4, Thomas Bardin5, Markus R. John6, Gerhard Krammer6, Jan Michael Nebesky6, Aiyang Tao7 and Naomi Schlesinger8, 1Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, 2Charité Univ Medicine, Berlin, Germany, 3Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Holdsworth House Medical Practice, Sydney, Australia, 5Rheumatology, Hôpital Lariboisière, Paris, France, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits.  CAN…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology